PAVILION HP NEW DV2000 SCREEN LCD 14.1" DV2500 Laptop Screens & LCD Panels


  1. Home
  2. PAVILION HP NEW DV2000 SCREEN LCD 14.1" DV2500
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
NEW HP PAVILION DV2000 DV2500 14.1"  LCD SCREEN
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Aspect Ratio: Wide Screen, 16:10
MPN:

HP 610395675846

Lamp Pins: 2 Pins
Technology: Active Matrix TFT Screen Finish: GLOSSY
Compatibility: 100% OEM Compatible Brand:

HP

Data Cable Pins: 30 Pins Resolution (Pixels): 1280 x 800
Grade: Brand New, A+ Premium Grade Width x Height: 12.5" x 8"
Resolution (Type): WXGA Backlight Lamp: CCFL
Warranty: 6 months / 180 days Diagonal Screen Size: 14.1 Inch Crossways
UPC:

610395675846

published on tue nov 09 2021

PAVILION HP NEW DV2000 SCREEN LCD 14.1" DV2500 Laptop Screens & LCD Panels

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

PAVILION HP NEW DV2000 SCREEN LCD 14.1" DV2500 Laptop Screens & LCD Panels

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS